Poor Housing Harms Health In American Indian

Results after 21 months showed that Pluvicto was more effective at delaying cancer progression. Among men who got the drug, it took 8.7 months on average for their tumors to start growing again, compared to 3.4 months among men who got standard of care.

Pluvicto was also associated with better overall survival: 15.3 months versus 11.3 months. The drug was generally well tolerated, but it also had side effects including fatigue, nausea, kidney problems, and bone marrow suppression.

Dr. David Einstein, a medical oncologist at Beth Israel Deaconess Medical Center in Boston and an assistant professor at Harvard Medical School, describes Pluvicto as a new and exciting tool.

Yet he cautioned that while the drug provides a welcome incremental advance for men with advanced prostate cancer, it is not a cure. “Some patients may get the message that Pluvicto replaces all the other available therapies, and this is definitely not the case,” he says.

Meanwhile, additional questions remain over who might be able to get the drug. “What about men with metastatic prostate cancer who were never treated with chemotherapy?” Dr. Einstein asks. “If you go strictly by the label,

Then prior chemotherapy is required. But some men are too sick for chemotherapy, or they may refuse it over potential side effects.” Researchers are now conducting studies to determine if Pluvicto is beneficial during earlier stages of prostate cancer, or if combining it with other therapies that might enhance its effects.

“The availability of this new treatment is important for several reasons,” said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, editor of Harvard Health Publishing’s Annual Report on Prostate Diseases, and editor in chief of HarvardProstateKnowledge.org.

“First, it extends survival among men who have been heavily treated already and have few therapeutic options remaining. Second, it represents a new approach to using radioactive substances that adds benefit to traditional medicine. And finally, it relies on a diagnostic scan that specifically identifies which men are most likely to benefit from the treatment.”

Robbed of ancestral lands, American Indian and Alaska Native tribal communities face an unparalleled housing crisis that pleads for national housing reforms. As victims of centuries of intentional government

Policies to remove and reallocate lands and resources, many live in third-world conditions that have led to sky-high rates of health problems, ranging from diabetes and cardiovascular disease to chronic liver disease, obesity, unintentional injuries, substance use disorders, violence, and suicides. This paves a path to extremely high rates of disability and prematurely shortened lives.

Poverty And Poor Housing Harm Health And Drive Disability

The stark reality of poverty became obvious when I traveled to my reservation home in Mescalero, New Mexico as a child. There I saw discolored, fractured, or weather-tattered homes, and yards littered with old, rusted, and abandoned cars.

According to the National Congress of American Indians, substandard housing makes up 40% of on-reservation housing compared to just 6% of housing outside of Indian Country. On reservations, almost one-third of homes are overcrowded.

In 2019, an estimated 20% of American Indian and Alaska Medical Native people lived in poverty compared to an 11% national poverty rate. Poverty, low education levels, and harsh conditions mean that many American Indians and Alaska Natives lack the foundation for basic survival: stable, secure, adequate, affordable housing. How Do I Get Weed

Results after 21 months showed that Pluvicto was more effective at delaying cancer progression. Among men who got the drug, it took 8.7 months on average for their tumors to start growing again, compared to 3.4 months among men who got standard of care. Pluvicto was also associated with better overall survival: 15.3 months versus…

Results after 21 months showed that Pluvicto was more effective at delaying cancer progression. Among men who got the drug, it took 8.7 months on average for their tumors to start growing again, compared to 3.4 months among men who got standard of care. Pluvicto was also associated with better overall survival: 15.3 months versus…